Sight Sciences (SGHT) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $20.2 million, up 1% year-over-year, with Surgical Glaucoma accounting for 92% and Dry Eye 8% of sales.

• OMNI and TearCare are flagship technologies, with over 240,000 OMNI and 60,000 TearCare procedures performed as of September 30, 2024.

• Net loss for Q3 2024 was $11.1 million ($0.22/share), improved from $13 million ($0.27/share) in Q3 2023.

• Gross margin declined to 84% from 87% in Q3 2023 due to higher overhead per unit.

• Organizational changes, executive hires, and commercial execution enhancements are underway to drive future growth.

Financial highlights

• Q3 2024 revenue: $20.2 million, up 1% year-over-year; nine months ended September 30, 2024: $60.8 million, down 2.4% year-over-year.

• Surgical Glaucoma Q3 2024 revenue: $18.6 million, up 1% year-over-year; Dry Eye: $1.5 million, down 4% year-over-year but ahead of expectations.

• Gross margin: 84% in Q3 2024, down from 87% in Q3 2023.

• Net loss: $11.1 million ($0.22/share) in Q3 2024; cash and equivalents: $118.6 million; debt: $35 million.

• Cash used in first nine months of 2024: $19.6 million, down from $40.5 million in prior year.

Outlook and guidance

• Full-year 2024 revenue guidance maintained at $81–83 million; adjusted operating expense guidance revised down to $104–106 million.

• Double-digit Surgical Glaucoma revenue growth expected in Q4 2024 year-over-year.

• Q4 2024 Dry Eye revenue expected below $0.5 million due to price increase, with growth anticipated to resume in 2025.

• Confident in achieving cash flow break-even without raising additional equity; sufficient liquidity for at least 12 months.

• Strategic focus on expanding OMNI and TearCare utilization, optimizing reimbursement, and international growth.